Precision Medicine in Childhood Cancer: The Influence of Genetic Polymorphisms on Vincristine-Induced Peripheral Neuropathy
Metadatos
Mostrar el registro completo del ítemAutor
Marangoni-Iglecias, Luciana María; Rojo-Tolosa, Susana; Márquez Pete, Noelia; Cura, Yasmin; Moreno-Toro, Noelia; Membrive Jiménez, Cristina; Sánchez Martín, Almudena; Pérez Ramírez, Cristina; Jiménez Morales, AlbertoEditorial
MDPI
Materia
Vincristine Peripheral neuropathy Pediatric oncology
Fecha
2024-08-13Referencia bibliográfica
Marangoni-Iglecias, L.; Rojo-Tolosa, S.; Márquez-Pete, N.; Cura, Y.; Moreno-Toro, N.; Membrive-Jiménez, C.; Sánchez-Martin, A.; Pérez-Ramírez, C.; Jiménez-Morales, A. Precision Medicine in Childhood Cancer: The Influence of Genetic Polymorphisms on Vincristine-Induced Peripheral Neuropathy. Int. J. Mol. Sci. 2024, 25, 8797. https://doi.org/10.3390/ijms25168797
Patrocinador
ERDF funds (EU) from the Instituto de Salud Carlos III (PT13/0010/0039) supported by co-funding grants from the Biobank of the Hospital Universitario Virgen de las NievesResumen
Cancer is the leading cause of disease-related death among children. Vincristine (VCR),
a key component of childhood cancer treatment protocols, is associated with the risk of peripheral
neuropathy (PN), a condition that may be reversible upon drug discontinuation but can also leave
lasting sequelae. Single nucleotide polymorphism (SNP) in genes involved in VCR pharmacokinetics
and pharmacodynamics have been investigated in relation to an increased risk of PN. However,
the results of these studies have been inconsistent. A retrospective cohort study was conducted to
investigate the potential association of drug transporter genes from the ATP-binding cassette (ABC)
family and the centrosomal protein 72 (CEP72) gene with the development of PN in 88 Caucasian
children diagnosed with cancer and treated with VCR. Genotyping was performed using real-time
PCR techniques for the following SNPs: ABCB1 rs1128503, ABCC1 rs246240, ABCC2 rs717620, and
CEP72 rs924607. The results indicated that age at diagnosis (OR = 1.33; 95% CI = 1.07–1.75) and the
ABCC1 rs246240 G allele (OR = 12.48; 95% CI = 2.26–100.42) were associated with vincristine-induced
peripheral neuropathy (VIPN). No association was found between this toxicity and CEP72 rs924607.
Our study provides insights that may contribute to optimizing childhood cancer therapy in the future
by predicting the risk of VIPN